Drug Trial Radar · NCT06761898
A Study of Different Forms of BGB-43395 and Food Effect in Healthy Participants
Last checked: Nov 20, 2026Latest source record: Sep 4, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
51
Actual
Start
Jan 14, 2025
Primary completion
May 20, 2025
Study completion May 20, 2025
Sponsor
- Lead sponsor
- BeiGeneBeOne Medicines (BeiGene) (ONC)
- Sponsor type
- Industry
- First posted
- Jan 7, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Study to determine the relative bioavailability of BGB-43395 solid dispersion tablet compared to salt tablet in healthy adult participants in Part 1 and the effect of food on the selected BGB-43395 formulation solid dispersion tablet or salt tablet in healthy adult participants in Part 2.
Conditions
- Healthy Volunteers
Interventions
BGB-43395Drug
Administered orally as solid dispersion tablet or salt tablet
BGB-43395Drug
Administered orally as solid dispersion tablet or salt tablet
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part 1 and 2: Area Under the Concentration-time Curve from Time 0 Extrapolated to Infinity (AUC0-∞)Time frame: PK is assessed on days 1-15 in Part 1 and Days 1- 22 for part 2
- Part 1 and 2: Area Under the Concentration-time Curve from Time 0 to the Time of the Last Quantifiable Concentration (AUC0-tlast)Time frame: PK is assessed on days 1-15 in Part 1 and Days 1- 22 for part 2
- Part 1 and 2: Maximum Observed Concentration (Cmax)Time frame: PK is assessed on days 1-15 in Part 1 and Days 1- 22 for part 2
- Part 1 and 2: Time of the Maximum Observed Concentration (Tmax)Time frame: PK is assessed on days 1-15 in Part 1 and Days 1- 22 for part 2
- Part 1 and 2: Apparent Terminal Elimination Half-life (t1/2)Time frame: PK is assessed on days 1-15 in Part 1 and Days 1- 22 for part 2
- Part 1 and 2: Apparent Total Clearance (CL/F)Time frame: PK is assessed on days 1-15 in Part 1 and Days 1- 22 for part 2
- Part 1 and 2: Apparent Volume of Distribution (Vz/F)Time frame: PK is assessed on days 1-15 in Part 1 and Days 1- 22 for part 2
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Fortrea Cru, Daytone Beach
Daytona Beach, Florida
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.